Amendments to the Claims:

1. - 10. (Canceled)

11. (Currently Amended) A pharmaceutical composition comprising a compound of formula ~~(I)~~(Ia), ~~as described in~~ according to claim ~~1~~14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

12. (Currently Amended) A combination comprising a compound of formula ~~(I)~~(Ia), as ~~described in~~ according to claim ~~1~~14, or a pharmaceutically acceptable salt~~, solvate or pro-drug~~ thereof, and at least one other therapeutically active agent.

13. (Original) A combination according to claim 12, wherein the other therapeutically active agent is a PDEV inhibitor.

14. (New) A compound of formula (Ia):



(Ia)

wherein R^a is selected from halogen, hydroxy, (C_1-C_6)alkoxy, cyano, nitro, amino, hydroxycarbonyl,

C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,

hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,

C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,

C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,

C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,

C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,

aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,

3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

R^b is selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy cyano, nitro, amino, hydroxycarbonyl,

C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,

hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,

C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,

C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,

C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,

C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,

aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,

3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

or a pharmaceutically acceptable salt thereof.

15. (New) A compound of formula (Ib):



(Ib)

wherein R^a is selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy, C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl, C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino, C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino, aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

R^b is selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy cyano, nitro, amino, hydroxycarbonyl, C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy, C_1-C_6 alkylamino, di-C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl, C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino, C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino, aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt thereof.

16. (New) A compound of formula (Ic):



(Ic)

wherein R^a and R^b are independently selected from hydrogen, halogen, hydroxy, (C_1-C_6)alkoxy, cyano, nitro, amino, hydroxycarbonyl,
C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl,
hydroxyC_1-C_6 alkyl, C_1-C_6 alkoxyC_1-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC_1-C_6 alkoxy,
C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC_1-C_6 alkyl, di-C_1-C_6 alkylaminoC_1-C_6 alkyl,
C_1-C_6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC_1-C_6 alkyl, C_1-C_6 acylamino,
C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl,
C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino,
aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl,
3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;
or a pharmaceutically acceptable salt thereof.

17. (New) A compound of formula (Ia) according to claim 1 which is:
(2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

18. (New) A compound of formula (Ib) according to claim 15 which is selected from the group consisting of:
(2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid;
(2*S*,4*S*)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; and
(2*S*,4*S*)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

19. (New) A compound of formula (Ic) according to claim 16 which is selected from the group consisting of:
(2*S*,4*S*)-4-(3-Fluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid;

(2*S*,4*S*)-4-(3,6-Difluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid;
(2*S*,4*S*)-4-(2,3-Difluoro-phenoxymethyl)-pyrrolidine-2-carboxylic acid; and
(2*S*,4*S*)-4-(3-Methoxy-phenoxymethyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

20. (New) A pharmaceutical composition comprising a compound of formula (Ib) according to claim 15, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

21. (New) A combination comprising a compound of formula (Ib) according to claim 15, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

22. (New) A combination according to claim 21, wherein the other therapeutically active agent is a PDEV inhibitor.

23. (New) A pharmaceutical composition comprising a compound of formula (Ic) according to claim 16, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

24. (New) A combination comprising a compound of formula (Ic) according to claim 16, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

25. (New) A combination according to claim 24, wherein the other therapeutically active agent is a PDEV inhibitor.

26. (New) The compound (2S,4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt thereof.